Folgen
Kelli M Luginbuhl
Kelli M Luginbuhl
Isolere Bio, Inc.
Bestätigte E-Mail-Adresse bei duke.edu
Titel
Zitiert von
Zitiert von
Jahr
A depot-forming glucagon-like peptide-1 fusion protein reduces blood glucose for five days with a single injection
M Amiram, KM Luginbuhl, X Li, MN Feinglos, A Chilkoti
Journal of controlled release 172 (1), 144-151, 2013
1362013
A brush-polymer/exendin-4 conjugate reduces blood glucose levels for up to five days and eliminates poly (ethylene glycol) antigenicity
Y Qi, A Simakova, NJ Ganson, X Li, KM Luginbuhl, I Ozer, W Liu, ...
Nature biomedical engineering 1 (1), 0002, 2016
1342016
Injectable protease-operated depots of glucagon-like peptide-1 provide extended and tunable glucose control
M Amiram, KM Luginbuhl, X Li, MN Feinglos, A Chilkoti
Proceedings of the National Academy of Sciences 110 (8), 2792-2797, 2013
1272013
One-week glucose control via zero-order release kinetics from an injectable depot of glucagon-like peptide-1 fused to a thermosensitive biopolymer
KM Luginbuhl, JL Schaal, B Umstead, EM Mastria, X Li, S Banskota, ...
Nature biomedical engineering 1 (6), 0078, 2017
1142017
Genetically encoded lipid–polypeptide hybrid biomaterials that exhibit temperature-triggered hierarchical self-assembly
D Mozhdehi, KM Luginbuhl, JR Simon, M Dzuricky, R Berger, HS Varol, ...
Nature chemistry 10 (5), 496-505, 2018
902018
Recombinant synthesis of hybrid lipid–peptide polymer fusions that self‐assemble and encapsulate hydrophobic drugs
KM Luginbuhl, D Mozhdehi, M Dzuricky, P Yousefpour, FC Huang, ...
Angewandte Chemie International Edition 56 (45), 13979-13984, 2017
692017
Controlled release of biologics for the treatment of type 2 diabetes
CA Gilroy, KM Luginbuhl, A Chilkoti
Journal of Controlled Release 240, 151-164, 2016
612016
Quantitative proteomics identifies vasopressin-responsive nuclear proteins in collecting duct cells
LK Schenk, SJ Bolger, K Luginbuhl, PA Gonzales, MM Rinschen, MJ Yu, ...
Journal of the American Society of Nephrology 23 (6), 1008-1018, 2012
602012
Genetically encoded cholesterol-modified polypeptides
D Mozhdehi, KM Luginbuhl, M Dzuricky, SA Costa, S Xiong, FC Huang, ...
Journal of the American Chemical Society 141 (2), 945-951, 2019
402019
Ultrasensitive point-of-care immunoassay for secreted glycoprotein detects Ebola infection earlier than PCR
CM Fontes, BD Lipes, J Liu, KN Agans, A Yan, P Shi, DF Cruz, G Kelly, ...
Science translational medicine 13 (588), eabd9696, 2021
242021
Design of Sequence‐Specific Polymers by Genetic Engineering
D Mozhdehi, KM Luginbuhl, S Roberts, A Chilkoti
Sequence‐Controlled Polymers, 91-115, 2018
42018
494 Pisitkun T, and Knepper MA
LK Schenk, SJ Bolger, K Luginbuhl, PA Gonzales, MM Rinschen, MJ Yu, ...
Quantitative proteomics identifies vasopressin-responsive 495, 1008-1018, 0
4
Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
A Chilkoti, D Mozhdehi, KM Luginbuhl
US Patent 11,648,200, 2023
22023
Genetically encoded polypeptide for affinity capture and purification of biologics
KM Luginbuhl, A Chilkoti
US Patent App. 17/268,314, 2021
22021
Genetically encoded polypeptide for affinity capture and purification of biologics
KM Luginbuhl, A Chilkoti
US Patent 11,739,126, 2023
12023
IsoTag™ AAV: an innovative, scalable & non-chromatographic method for streamlined AAV manufacturing
J Haley, JB Jones, S Petraki, M Callander, S Shrestha, E Springfield, ...
Cell & gene therapy insights 8 (10), 1287, 2022
12022
Compositions and methods for improving lentiviral transduction
N Votaw, M Dzuricky, KM Luginbuhl
US Patent App. 18/351,209, 2024
2024
Genetically encoded polypeptide for affinity capture and purification of biologics
KM Luginbuhl, A Chilkoti
US Patent App. 18/346,456, 2024
2024
Compositions comprising aav-binding polypeptides and methods of using the same
KM Luginbuhl, L Hyun, M Dzuricky
US Patent App. 18/309,154, 2023
2023
Purification matrices comprising aav-binding polypeptides and methods of using the same
KM Luginbuhl, M Dzuricky, Z Elmore, A Asokan
US Patent App. 17/800,700, 2023
2023
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20